Form 4: Recursion Pharmaceuticals CEO Christopher Gibson Executes Stock Transactions

CEO Christopher Gibson reports the sale of 100,000 shares of Recursion Pharmaceuticals Class A Common Stock and the conversion of Class B Common Stock into Class A Common Stock.

Summary

• On July 10th and 11th, 2024, Christopher Gibson, CEO of Recursion Pharmaceuticals, engaged in transactions involving the company's stock.
• These transactions included the sale of 100,000 shares of Class A Common Stock at prices of $7.47 and $7.48.
• Additionally, 100,000 shares of Class B Common Stock were converted into Class A Common Stock.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, Gibson directly owns 758,738 shares of Class A Common Stock.
• Gibson also indirectly owns shares through LAHWRAN-3 LLC (486,000 shares), LAHWRAN-4 LLC (388,000 shares), and the Gibson Family Trust (67,875 shares).
• He also holds options to purchase a significant number of Class A Common Stock at various exercise prices and vesting schedules.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing simply reports transactions executed under a pre-existing trading plan. There's no inherent positive or negative signal.

Negatives

• The sale of shares by the CEO could be interpreted negatively by some investors.

Risks

• Continued sales of shares by insiders could put downward pressure on the stock price.

Industry Context

Insider transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. A pre-arranged trading plan under Rule 10b5-1, however, mitigates concerns about trading on inside information.

Comparison to Industry Standards

• It's common for executives at publicly traded companies, including those in the biotechnology sector like Recursion Pharmaceuticals, to have pre-arranged trading plans to diversify their holdings or manage personal finances.
• The volume of shares sold is relatively small compared to the total outstanding shares of RXRX.
• Comparing the CEO's transactions to those of executives at similar-stage biotech companies (e.g., those with market caps between $1 billion and $2 billion) shows that such sales are not uncommon, especially when part of a pre-defined plan.
• Companies like Exscientia or Relay Therapeutics also see regular insider trading activity.

Stakeholder Impact

• The transactions could have a minor impact on shareholder sentiment, depending on how they are interpreted.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates